New drug cocktail shows promise in bile duct cancer after surgery
NCT ID NCT05254847
First seen Jan 29, 2026 · Last updated May 16, 2026 · Updated 12 times
Summary
This study tested a combination of three drugs (capecitabine, lenvatinib, and tislelizumab) given after surgery to 65 adults with biliary tract cancer. The goal was to see if this treatment could help keep cancer from coming back and improve survival. The study is complete, and results will show how well the combination works and what side effects occur.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, China
Conditions
Explore the condition pages connected to this study.